Evinacumab is a recombinant human IgG4 monoclonal antibody targeting human angiopoietin-like protein 3 (ANGPTL3). The ANGPTL protein family has many physiological functions-including the regulation of lipid metabolism. It has been noted that the loss-of-function mutation of ANGPTL3 leads to hypolipidemia and subsequently reduces cardiovascular risk, while increased function seems to be related to cardiovascular risk. Evinacumab has been used to treat homozygous familial hypercholesterolemia (HoFH). It has been sold under the Evkeeza brand name.
There are no reviews yet.
Your email address will not be published. Required fields are marked *
In which application did you use the antibody? *
Did it work in your application? *
Your review *
Save my name, email, and website in this browser for the next time I comment.
Got a question or need a quote? Message us and we’ll get back to you 48 hours or less.
Lab / Company
in 2023, NO price increase on ProteoGenix products, to support your discoveries💥